Advances in the Development of Intralesional Therapies for Melanoma

Wang, Daniel; Johnson, Douglas B.

doi:10.2217/mmt-2016-0020

Cited by 5 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated that the cytotoxic effect of 1 mM RB had few side effects on normal tissues, and this dose is consistent with that used to treat melanoma in clinical trials [ 40 ]. Several studies have shown that RB intralesional injection trigger iDCs to migrate into the tumour [ 41 , 42 ], although occasionally, the DCs are not able to enter the TME due to the immunosuppressive nature of the TME, which leads to the insufficient infiltration of effective immune cells into the TME [ 34 ]. Therefore, the intralesional injection of both RB and iDCs could subvert these immunosuppressive effects and guarantee sufficient antigen presentation.…”

Section: Discussionmentioning

confidence: 99%

A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity

Zhang

Song

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Dendritic cell- (DC-) based vaccination has emerged as a promising antitumour immunotherapy. However, overcoming immune tolerance and immunosuppression in the tumour microenvironment (TME) is still a great challenge. Recent studies have shown that Rose Bengal (RB) can effectively induce immunogenic cell death (ICD) in cancer cells, presenting whole tumour antigens for DC processing and presentation. However, the synergistic antitumour effect of combining intralesional RB with immature DCs (RB-iDCs) remains unclear. In the present study, we investigated whether RB-iDCs have superior antitumour effects compared with either single agent and evaluated the immunological mechanism of RB-iDCs in a murine lung cancer model. The results showed that intralesional RB-iDCs suppressed subcutaneous tumour growth and lung metastasis, which resulted in 100% mouse survival and significantly increased TNF-α production by CD8+ T cells. These effects were closely related to the induction of the expression of distinct ICD hallmarks by RB in both bulk cancer cells and cancer stem cells (CSCs), especially calreticulin (CRT), thus enhancing immune effector cell (i.e., CD4+, CD8+, and memory T cells) infiltration and attenuating the accumulation of immunosuppressive cells (i.e., Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs)) in the TME. This study reveals that the RB-iDC vaccine can synergistically destroy the primary tumour, inhibit distant metastasis, and prevent tumour relapse in a lung cancer mouse model, which provides important preclinical data for the development of a novel combinatorial immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity

Zhang

Song

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Apart from this, other IL therapies including PV-10 (Rose Bengal), IL-12 plasmid electroporation, and Coxsackievirus A21 have shown favorable clinical outcomes. [ 60 ]…”

Section: P Ros a Ssociated With T Reatment Of Il A Gentsmentioning

confidence: 99%

Intralesional agents in dermatology: Pros and cons

Sakhiya¹,

Sakhiya

Kaklotar³

et al. 2021

J Cutan Aesthet Surg

View full text Add to dashboard Cite

“…The survival of patients with unresectable and metastatic melanoma has substantially improved over the last decade with the development of novel systemic immunotherapies, such as anti-CTLA-4 and anti-PD-1/anti-PD-L1 agents and targeted therapies [2]. Beyond systemic treatment, intratumoral therapies may benefit specific patient groups, for example, those with extensive and recurrent locoregional disease and high tumor burden [3]. Due to a relatively lower risk for toxicity, intratumoral therapies might be a valuable option in elderly patients with co-morbidities, where systemic treatment options are contraindicated [4].…”

mentioning

confidence: 99%

Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database

Louie

Banks²,

Scholz³

et al. 2020

Future Oncol.

View full text Add to dashboard Cite

Aim: There is a growing body of data on real-world use of talimogene laherparepvec (T-VEC). We aimed to characterize real-world T-VEC use using a nationally representative German prescription database covering 60% of prescriptions reimbursed. Patients & methods: A retrospective analysis was conducted using the German IMS® LRx prescription database, analyzing patients aged ≥18 years with an initial T-VEC prescription at 106 plaque-forming units (PFU)/ml and ≥1 subsequent prescription at 108 PFU/ml. Median time on T-VEC treatment, patient characteristics and patterns of T-VEC use were described. Results: Of 127 patients prescribed T-VEC, 72 patients (57%) met study criteria. About two-thirds of these patients initiated T-VEC in 2017. Median age at T-VEC initiation was 74 years (range: 44 to 91). Most prescriptions (88%) were dispensed from hospitals. At study end, 26 (36%) patients remained on T-VEC; 46 (64%) had ended treatment. Median duration of T-VEC treatment for all patients was 18.7 weeks (95% CI: 15.3–26.9) and was longer among those who initiated treatment in 2017 versus 2016 (26.7 vs 15.6 weeks, respectively). Median volume administered for the first 106 PFU/ml and second 108 PFU/ml was 4 ml; the volume decreased for subsequent administrations (2 ml by the eighth administration and 1 ml by the 16th administration). Conclusion: This real-world prescription database study showed that patients who initiated treatment in 2017 had a treatment duration in clinical practice that corresponded with the European Summary of Product Characteristics guideline of continuing T-VEC for ≥6 months. Additional long-term data linking drug use with clinical outcomes are needed.

show abstract

Advances in the Development of Intralesional Therapies for Melanoma

Cited by 5 publications

References 55 publications

A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity

A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity

Intralesional agents in dermatology: Pros and cons

Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database

Contact Info

Product

Resources

About